Wockhardt LimitedNSE: WOCKPHARMA

Press Release Jun 28 2024

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited submitted a press release regarding the award of high susceptibility breakpoints to Zaynich by the Clinical and Laboratory Standards Institute. The press release highlights that this is the first time an antibiotic has received such a high breakpoint for multiple Gram-negative pathogen families.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated Jun 28, 2024, titled "Globally renowned US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222)".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases